Johnson & Johnson (NYSE:JNJ) reports that a New Jersey district court ruled that all claim asserted under its U.S. Patent No. 8,822,438 are invalid, removing a hurdle for generic competitors to sell their versions of prostate cancer med ZYTIGA (abiraterone acetate).
The court also ruled that no commercial launches of generic products may occur prior to October 31. An appeal is next up.
JNJ reaffirms its 2018 guidance of 5.5 - 6.0% sales growth and non-GAAP EPS of $8.13 - 8.18.
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn
Mark H. Anania, a partner at McCarter & English, LLP, has been named President of the New Jersey Intellectual Property Law Association
Cohen Seglias Pallas Greenhall & Furman PC is pleased to announce that Anthony H. Chwastyk has joined the
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2024 citybuzz
